Join us for a virtual KOL event featuring Fiona Simpkins, MD (Perelman School of Medicine, University of Pennsylvania) and Timothy A. Yap, MBBS, PhD, FRCP (University of Texas MD Anderson Cancer Center) who will discuss the current landscape of treatments and investigational drugs for patients with advanced solid tumors, focused on DNA damage response (DDR) pathways and their role in tumor suppression.

The Aprea Therapeutics team will discuss the Phase 1/2a study evaluating its lead program of a highly potent and selective macrocyclic inhibitor of ataxia telangiectasia and Rad3-related (ATR), ATRN-119, in patients with advanced solid tumors having mutations in defined DDR genes. The event will also highlight Aprea’s preclinical WEE1 inhibitor, ATRN-1051, with IND filing anticipated by the end of 2023, including the clinical development strategy for the study of ATRN-1051.

An interactive question and answer session will follow the formal presentations.